Jim Cramer on Kenvue: “I Think It is a Good Situation, Not a Bad One”

Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if long-term shareholders should be worried. Here’s what Mad Money’s host had to say in response:

“Okay, it’s a really important question because I’ve been looking to buy Kimberly. I think the answer is no. I think you’ll be fine. There’s going to be lawsuits. We’ve dealt with them before. Look at Johnson & Johnson… I think it is a good situation, not a bad one.”

A person with stock market data on a laptop. Photo by Anna Nekrashevich on Pexels

Kenvue Inc. (NYSE:KVUE) provides consumer health products across pain relief, allergy care, digestive support, wellness, and personal care under its brands. Some of its products include Tylenol, Motrin, Calpol, Neutrogena, and Band-Aid. A caller mentioned the company’s litigation during the September 18 episode, and Cramer responded:

“I don’t think the litigation risk is nearly as bad as people think. This stock is at 4.5%. It’s got new leadership. I don’t want to dump it right here. I just don’t, but I don’t expect a lot of upside here. That’s the problem.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.